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Elucidating how the brain’s serotonergic network mediates diverse behavioral actions over both relatively short (minutes–hours) and long
period of time (days–weeks) remains a major challenge for neuroscience. Our relative ignorance is largely due to the lack of technologies
with robustness, reversibility, and spatio-temporal control. Recently, we have demonstrated that our chemogenetic approach (eg, Designer
Receptors Exclusively Activated by Designer Drugs (DREADDs)) provides a reliable and robust tool for controlling genetically defined
neural populations. Here we show how short- and long-term activation of dorsal raphe nucleus (DRN) serotonergic neurons induces
robust behavioral responses. We found that both short- and long-term activation of DRN serotonergic neurons induce antidepressant-like
behavioral responses. However, only short-term activation induces anxiogenic-like behaviors. In parallel, these behavioral phenotypes were
associated with a metabolic map of whole brain network activity via a recently developed non-invasive imaging technology DREAMM
(DREADD Associated Metabolic Mapping). Our findings reveal a previously unappreciated brain network elicited by selective activation of
DRN serotonin neurons and illuminate potential therapeutic and adverse effects of drugs targeting DRN neurons.
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INTRODUCTION
The brain’s serotonergic network is a large and complex
efferent system that controls a highly diverse range of
behavioral and physiological processes, including perception,
mood, anxiety, food intake, and circadian rhythm (Berger
et al, 2009). Brain serotonergic neurons are distributed in a
series of predominantly midline raphe nuclei extending from
the midbrain to the caudal medulla and projecting widely
throughout the brain and spinal cord (Jacobs and Azmitia,
1992). The midbrain dorsal raphe nucleus (DRN) is the
largest of the raphe nuclei, and DRN serotonergic neurons
project rostrally to provide the predominant serotonergic
innervation of the forebrain (Vertes, 1991; Jacobs and
Azmitia, 1992; Waselus et al, 2012). Dysregulation of DRN
serotonergic neurotransmission has been implicated in many
psychiatric illnesses, such as anxiety and depressive disorders
(Graeff et al, 1996; Underwood et al, 1999; Lowry et al, 2008).
Additionally, enhancement of DRN serotonin (5-HT) release
has been proposed to be responsible for the actions of some
antidepressants (Stamford et al, 2000).
Despite the fact that many commonly prescribed and
abused serotonergic drugs (eg, fluoxetine, 3,4-methylene-
dioxy-methamphetamine) globally modulate serotonergic
neurotransmission, the precise mechanism(s) responsible
for both their therapeutic and adverse effects remain unclear.
To address this challenge, we employed an approach
enabling selective control of specific serotonergic nuclei.
Selective manipulation of the DRN serotonergic neurons
has been proven difficult as many (50–75%) neurons in the
DRN are non-serotonergic (Halberstadt and Balaban, 2008).
Additionally, although optogenetic approaches are useful for
the acute (eg, seconds–minutes) control of specific 5-HT
neurons, optogenetic approaches are not particularly suited
for mimicking the types of long-term modulation of 5-HT
neuronal activity induced by drugs which exert their actions
over a prolonged period of time.
Here we show that the hM3Dq DREADD (Designer
Receptor Exclusively Activated Designer Drug), which is
coupled to Gαq signaling pathway and acted as a global
neuronal activation tool (Armbruster et al, 2007; Rogan and
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Roth, 2011), remotely controls DRN serotonergic neurons for
both short (hours) and long (weeks) duration studies.
We discovered that short- and long-term activation of DRN
5-HT neurons induces both similar and divergent behavioral
programs, which mimic multiple actions of antidepressant
drugs. In parallel, we associated these behavioral changes with
alterations in whole brain metabolic activity using a newly
developed technology (eg, DREADD Assisted Metabolic
Mapping (DREAMM); Michaelides et al, 2013; Michaelides
and Hurd, 2015).
MATERIALS AND METHODS
Animal Subjects and General Procedures
All procedures were conducted in accordance with the Guide
for the Care and Use of Laboratory Animals, as adopted
by the National Institutes of Health, and with approval
of the Institutional Animal Care and Use Committees at
the University of North Carolina (UNC), Duke University,
and the University of California at San Francisco. Adult, age-
matched, male Slc6a4-Cre mice (MMRRC: Stock number—
017260UCD) were used for all in vivo and ex vivo
experiments.
Stereotaxic Injection
Adult (22–30 g) male Slc6a4-Cre males (017260UCD,
MMRRC) were used in current study. Unless described
otherwise, all mice were maintained on a standard 12-h light/
dark cycle with ad libitum access to food and water. Mice
were anesthetized with a ketamine (100 mg/kg) and xylazine
(10 mg/kg) solution and placed into a stereotaxtic frame
(Kopf Instruments). Mice were bilaterally injected with
0.75–1 μl (depending on viral titer) of adeno-associated virus
(AAV) into the dorsal raphe using the following stereotaxtic
coordinates: − 4.6 AP, ± 1.93 ML, and − 3.46 DV at an angle
of 30°. Dorsal raphe neurons were transduced with virus
encoding the hM3Dq-mCherry or EGFP in reverse orienta-
tion flanked by two lox sites (lox P and lox 2722) under the
control of the human synapsin (SYN1) promoter. Following
surgery, mice were individually housed and monitored for
signs of complications until they recovered from surgery. We
performed all experiments 4–16 weeks after surgery. All viral
constructs were packaged by the UNC Vector Core Facility.
After all experiments, each mouse was perfused and
validated for injection efficiency and viral expression.
Immunohistochemistry
Mice were anesthetized with tribromoethanol and then
perfused with 4% paraformaldehyde (PFA) in PBS. Brains
were dissected and postfixed overnight at 4 °C in 4% PFA,
followed by dehydration in a 30% sucrose solution in PBS for
48 h. Brain sections (40 μm) were permeabilized for 20 min
with 0.3% Triton X-100 in PBS and then blocked in blocking
buffer (PBS containing 0.3% Triton X-100, 2% normal goat
serum, and 3% bovine serum albumin) for 1 h at room
temperature. Slides were incubated with first antibody in
blocking buffer overnight at 4 °C. Primary antibodies used
in the studies were: anti-RFP (mouse, 1 : 1000, Abcam),
anti-5-HT (rabbit, 1 : 500, Immunostar) (for cell bodies) and
1 : 5000 (Sigma-Aldrich) (for axons), and anti-GFP (mouse,
1 : 500, Abcam). Slides were washed and incubated
with secondary fluorescent-conjugated antibodies (1 : 250,
Invitrogen) at room temperature (RT) for 1 h. After an
additional three washes, slides were mounted and fluorescent
images were collected on either a Nikon 80i Research
Upright Microscope (Nikon) equipped with the Surveyor
Software with TurboScan (Objective Imaging) or an
Olympus Fluoview FV1000 Laser Scanning Confocal Micro-
scope (Olympus). The images of coronal slices were analyzed
using the Image-J software (NIH).
Slice Electrophysiology
Brain slices were prepared for slice electrophysiology as
previously described (Marcinkiewcz et al, 2014). Briefly,
brains were sectioned at 0.07 (mm/s) to obtain 300 μm
coronal slices of the DRN. In a recording chamber, slices
were submerged in normal, oxygenated aCSF (28–30 °C,
2 ml/min flow rate) for at least 30 min before performing
whole-cell patch clamp experiments. Borosilicate electrodes
with a pipette filled with internal solution ((in mM): 135
KCl-gluconate, 5 NaCl, 2 MgCl2, 10 HEPES, 0.6 EGTA,
4 ATP, and 0.4 GTP, pH= 7.35, 290 mOsmol) were used
to patch cells in the DRN. Signals were acquired using a
Multiclamp 700B amplifier and analyzed with the Clampfit
10.3 software (Molecular Devices, Sunnyvale, CA, USA). The
effects of clozapine-N-oxide (CNO) were determined in
current clamp mode. After a 5-min stable baseline, CNO
(10 μM) was bath applied for 10 min while recording changes
in membrane potential. For excitability experiments, the
current threshold (rheobase) necessary to induce cell firing
were determined in current clamp mode using a current
ramp protocol from 0 to 100 pA. Next, a 10-pA current step
protocol from 0 to 200 pA was applied, from which V–I plots
were determined (ie, the number of action potentials vs
current). Synaptic transmission was assessed in voltage
clamp mode by using a cesium methanesulfonate-based
intracellular solution. Spontaneous excitatory postsynaptic
currents (sEPSCs) were recorded at − 55 mV (the reversal
potential for GABAA-mediated events) and spontaneous
postsynaptic inhibitory currents (sIPSCs) were recorded at
+10 mV (the reversal potential for AMPAR-mediated events).
After a 4-min baseline, we averaged the next two, 2-min files
to obtain the frequency and amplitude of sEPSCs, sIPSCs,
and the ratio of sEPSCs to sIPSCs (E/I ratio). For each cell,
we then determined the synaptic drive ratio (EPSC
frequency × amplitude)/(IPSC frequency × amplitude). The
average delta MP for hM3Dq and EGFP cells after CNO
was analyzed using a one-sample t-test in which the mean
was compared with a theoretical mean of zero. Resting
membrane potential (RMP), rheobase, and E/I ratios were
analyzed using Student’s t-tests. V–I plots were analyzed
using a two-way analysis of variance (ANOVA) with viral
vector and current as variables.
Behavioral Studies
For acute CNO experiments, each behavioral paradigm was
separated at least 1 week for a wash-out period.
Activation of DRN in behavioral responses
DJ Urban et al
1405
Neuropsychopharmacology
Locomotor activity and center zone time. Locomotor
activity was assessed under standardized environmental
conditions in 40 × 40 × 30 cm3 Plexiglas chambers with a
grid of photo-beams spaced at 1.52 cm (VersaMax system;
AccuScan Instruments). Locomotor activity was recorded
for 1 h. Data were extracted using the Fusion software
(AccuScan Instruments) as described (Farrell et al, 2013).
Light–dark emergence test. Light and dark preference was
assessed under standardized environmental conditions
in 40 × 40 × 30 cm3 Plexiglas chambers as described above,
fit with a 16" L× 8" H× 5" W dark chamber on one side
(VersaMax system; AccuScan Instruments). Time spent in
the light, dark, and doorway zones were recorded for 10 min.
Data were extracted using the VersaMap software (AccuScan
Instruments).
Forced swim. Mice were individually placed into a
Plexiglas cylinder (21 cm diameter, 28 cm height) containing
15 cm water (25± 0.5 °C) and were monitored for 6 min.
Mobility, high mobility, and immobility bouts were analyzed
using EthoVision XT7 for the last 4 min of the test. After the
swim session, mice were dried and placed in their home cage
surrounded by a cotton cloth. The water was changed in
between each animal.
Novelty-suppressed feeding. Food was removed from
the home cage 24 h before testing. Mice were weighed
just before food deprivation and again before testing to
assess body weight loss. For testing, mice were placed
into a brightly lit open field (40 cm×40 cm× 30 cm white
plastic boxes containing 2 cm of bedding) with a food
pellet at the center. Latency to begin eating the food
was recorded. The total amount of food consumed during
a 5 min period after returning to the home cage was
measured to test whether feeding differences in the novel
environment were due to differences in hunger/motivation.
These studies were performed after the first 4 h of the
light cycle.
Home cage monitoring (HCM) system. A detailed descrip-
tion of the HCM hardware has been reported elsewhere
(Goulding et al, 2008). Briefly, all animals were acclimated to
the HCM cages for 1 week, and then baseline data (days
8–15) were collected. After that, CNO was provided in the
drinking water at a concentration of 40 mg/l. Chronic CNO
treatment data were collected from day 22 to day 29. Data
collected during the 7-day periods (days 8–15 and 22–29)
were used for within-subject comparisons of behavioral
patterns at baseline vs during CNO treatment, respectively.
The impact of DRN serotonergic neuronal activation on
exploratory behavior was examined during the CNO chronic
treatment period. We examined the responses of CNO-
treated Slc6a4-hM3Dq and Slc6a4-EGFP mice to a novel
object placed within their HCM cages. Four hours prior to
the dark cycle onset, a metal binder clip (2 inch wide, 1 inch
capacity; Officemate International) was affixed to the center
of the long cage wall opposite the housing niche for a period
of 4 h. Exploratory responses to novel object presentation
were assessed by analyzing locomotor paths and determining
the amount of time animals spent within a 7 cm radius of the
object during the first hour of exposure.
DREADD-assisted metabolic mapping. Mice were trans-
ported to the μPET facility the day prior to each scan
to ensure habituation to the transportation procedure and
environment. All mice were fasted overnight to attain
consistency in blood glucose levels as abnormal blood
glucose levels interfere with [18F] fluorodeoxyglucose
(FDG) uptake (Wong et al, 2011). The following morning
mice received an injection (i.p.) of either vehicle or CNO
(2 mg/kg). This occurred four times, twice before
(acute-vehicle and acute-CNO) and twice after 3 weeks of
daily (5 mg/kg, p.o.) CNO exposure (chronic-vehicle and
chronic CNO). Therefore, each mouse was scanned four
times. For each acute and chronic phase, vehicle and CNO
scans were separated by two days. For acute phase scans,
vehicle preceded CNO while for chronic phase scans, CNO
preceded the vehicle (for the purpose of minimizing
withdrawal effects owing to disruption of daily CNO
administration after chronic exposure). Twenty minutes
after vehicle or CNO injections, mice received an injection (i.
p.) of ~ 0.2 mCi of FDG and were immediately placed in an
open-field arena (40.64 × 40.64 × 40.64 cm3) coupled to an
activity monitoring system (Truscan, Coulbourn Instru-
ments). Thirty minutes later, mice were anesthetized with
1.5% isoflurane, placed in a prone position on the bed of an
R4 microPET rodent scanner (Siemens Medical Solutions),
and scanned using a 20-min static acquisition protocol.
Scanning procedures, image processing, and analysis
were performed as previously described (Michaelides et al,
2010, 2013).
RESULTS
Selective Expression of hM3Dq DREADD in Serotonergic
Neurons in DRN
To selectively express hM3Dq DREADD in serotonergic
neurons in the DRN, we generated a rAAV8 vector construct
containing a double-floxed inverted open-reading frame
(DIO) sequence encoding hM3Dq-mCherry driven by a
human synapsin promoter. The inverted hM3Dq-mCherry
was then recombined into a correct orientation only in
the cre-recombinase-expressing cells (Sohal et al, 2009).
We stereotaxically injected this cre-dependent AAV8 virus
(Krashes et al, 2011) into the DRN of Slc6a4-Cre mice, in
which cre-recombinase was expressed in adult serotonergic
neurons (Gong et al, 2007) (Figure 1a). Three weeks after
injection, immunofluorescence staining was performed to
determine the co-localization and transduction efficiency of
DREADD virus. Immunofluorescence microscopy revealed
that hM3Dq DREADD was selectively expressed in DRN
(Figure 1b) and 96.7± 1.6% (N= 3670 cells) of hM3Dq
expressing neurons co-localized with 5-HT positive neurons
with a 64.2± 5.3% (N= 3670 cells) transduction efficiency
in DRN 5-HT-containing neurons (Figure 1c). A similar
degree of co-localization and transduction efficiencies were
also observed in Slc6a4-Cre mice stereotaxically injected with
a control cre-dependent EGFP AAV virus (97.7± 1.2%
co-localization, N= 2035 cells; 73.5± 4.6% transduction
efficiency, N= 2035 cells; Supplementary Figure S1). In
Activation of DRN in behavioral responses
DJ Urban et al
1406
Neuropsychopharmacology
addition, 5-HT positive axons emanating from the DRN
co-localized with hM3Dq receptors, thus demonstrating
efficient trafficking of the hM3Dq receptor to the axons of
DRN serotonergic neurons (Figure 1c). Importantly, there
was negligible expression of hM3Dq in 5-HT-positive
neurons of the median raphe nucleus (hM3Dq: 2.3± 3.0%;
N= 586 cells; Figure 1c), further highlighting selective
expression of hM3Dq in 5-HT-positive neurons in DRN.
Acute Activation of DRN Serotonergic Neurons Induces
Anxiogenic and Antidepressant Drug-Like Behavioral
Responses
After verifying selective expression of DREADD receptors in
DRN serotonergic neurons, we assessed the electrophysio-
logical properties of these neurons by activating hM3Dq
receptors (Figure 2a). After CNO exposure, a significant
increase in membrane potential was observed in
Figure 1 Selective expression of the hM3Dq DREADD in DRN serotonergic neurons of Slc6a4-Cre mice. (a) Schematic demonstration of the design and
stereotaxic injection of the cre-dependent hM3Dq-mCherry AAV driven off the human synapsin promoter. (b) mCherry fluorescence in the DRN
after injections of the AAV-hSyn-DIO-hM3Dq-mCherry virus into Slc6a4-Cre mice (scale: 200 μm). (c) Upper panels: co-localization of mCherry (Red) and
5-HT (Green) in the dorsal raphe nucleus (DRN). The hM3Dq DREADD receptor is expressed in the plasma membrane while 5-HT is in the cytoplasm
(scale: 10 μm). Middle panels: co-localization of hM3Dq receptor (Red) with 5-HT-positive axons (Green) projecting from the DRN (scale: 50 μm).
Lower panels: lack of expression and co-localization of hM3Dq receptor (Red) with 5-HT-positive neurons (Green) in the median raphe nucleus (MRN)
(scale: 50 μm).
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hM3Dq-positive DRN neurons (t(4)= 12.06, p= 0.0003,
Figure 2b and c) but not in EGFP-expressing neurons
(t(4)= 1.182, p= 0.3028)—in agreement with many previous
studies (Alexander et al, 2009; Krashes et al, 2011,
2014; Garfield et al, 2015). Importantly, hM3Dq-expressing
neurons had similar RMPs compared with EGFP-expressing
control neurons (Figure 2d).
DRN serotonergic neurons have long been implicated in
the actions of both anxiolytics and antidepressants, and we
predicted that activation of these neurons would mimic the
actions of these drugs. Initially, two anxiolytic paradigms,
light–dark emergence test and open-field test, were tested
45 min after acute CNO (2mg/kg) administration. As shown
in Figure 2e and f, acute activation of DRN neurons induced
relatively modest, though statistically significant, anxiogenic-
like responses in light–dark emergence test. CNO-treated
Slc6a4-hM3Dq mice displayed a significant reduction of time
spent in the lighted chamber and a reciprocal increase of
time spent in the darkened chamber (genotype × chamber,
F(2,78)= 9.16, p= 0.0003, two-way ANOVA Figure 2e).
A similar anxiogenic-like response was also manifested by
a significantly decreased center time in the open field in
Figure 2 Acute activation of DRN serotonergic neurons induces anxiogenic and antidepressant drug-like behavioral responses. (a) Schematic diagram of
acute CNO treatment experiments. (b) Representative trace and (c) bar graph showing average change in membrane potential in hM3Dq (N= 5) and EGFP
(N= 5) neurons. After a 5-min baseline, CNO (10 μM) was bath applied for 10 min. ***po0.001 (d) Average resting membrane potential (RMP) of hM3Dq
and EGFP neurons. (e) Time spent in the lighted, darkened, or doorway compartments by Slc6a4-hM3Dq (N= 15) and Slc6a4-EGFP (N= 13) mice over a
10-min period following acute administration of CNO (*po0.05). (f) Time spent in the center of an open field by Slc6a4-hM3Dq (N= 16) and Slc6a4-EGFP
(N= 16) mice shown in 5-min binned intervals after acute CNO administration. Inset: Total center time for the 60-min trial (*po0.05). (g) Time spent in the
lighted, darkened, or doorway compartments by Slc6a4-hM3Dq (N= 8) and Slc6a4-EGFP (N= 8) mice over a 10-min period following acute administration of
vehicle. (h) Time spent in the center of an open field by Slc6a4-hM3Dq (N= 8) and Slc6a4-EGFP (N= 8) mice in 5-min binned intervals after acute vehicle
administration. Inset: Cumulative center time for the 60-min test. (i) Percentage of time Slc6a4-hM3Dq (N= 9) and Slc6a4-EGFP (N= 9) mice exhibited
immobility, mobility, and high mobility during the last 4-min of the forced swim test after acute injection of CNO (*po0.05). (j) Percentage of time Slc6a4-
hM3Dq (N= 9) and Slc6a4-EGFP (N= 9) mice exhibited immobility, mobility, and high mobility during the last 4-min of the forced swim test after acute
administration of vehicle.
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CNO-treated Slc6a4-hM3Dq mice (t(1,30)= 2.246, p= 0.0322,
Figure 2f) without alterations of locomotion profiles (Supple-
mentary Figure S2). Importantly, these anxiogenic responses
were not observed in vehicle-treated Slc6a4-hM3Dq mice,
suggesting that these behaviors were specifically induced by
activating hM3Dq DREADD (Figure 2g and h).
Next, we wondered whether acutely activating the hM3Dq
receptors in the DRN could induce antidepressant-like
responses in the forced swim test similar to the actions
of many clinically effective antidepressants. Following
acute CNO administration, Slc6a4-hM3Dq mice displayed
a significant reduction in immobility when compared
with Slc6a4-EGFP control mice (F(2,48)= 5.86, p= 0.0006,
Figure 2i) without altering locomotion (Supplementary
Figure S2). Again, these antidepressant-like responses were
not observed in Slc6a4-hM3Dq mice if vehicle was adminis-
tered (Figure 2j).
Chronic Activation of DRN Serotonergic Neurons
Induces Antidepressant Drug-Like Behavioral Responses
The serotonergic system is a major target of many anti-
depressant drugs and in humans it typically requires
weeks for optimal effects to be observed (Quitkin et al,
Figure 3 Chronic activation of the DRN serotonergic neurons induces antidepressant-like responses. (a) Schematic diagram of chronic CNO treatment
experiments. Animals were chronically administered with CNO (5 mg/kg/day) in the drinking water for 3–4 weeks and then tested in the electrophysiology
or behavioral paradigms (b) Representative trace and (c) bar graph showing average change in membrane potential in hM3Dq (N= 4) and EGFP
(N= 8) neurons from mice treated chronically with CNO (5 mg/kg/day) for 3 weeks. After a 5-min baseline, CNO (10 μM) was bath applied for 10 min
(* po0.05). (d) Average resting membrane potential (RMP) of hM3Dq and EGFP neurons. (e) Time spent in the lighted, darkened, or doorway
compartments by Slc6a4-hM3Dq (N= 17) and Slc6a4-EGFP (N= 17) mice over a 10-min period. (f) Time spent in the center zone of an open field by Slc6a4-
hM3Dq (N= 17) and Slc6a4-EGFP (N= 17) mice in 5-min binned intervals. (g) Percentage of time Slc6a4-hM3Dq (N= 13) and Slc6a4-EGFP (N= 13) mice
engaged in immobility, mobility, and high mobility during the last 4-min of the forced swim test (*po0.05). (h) Percentage of time Slc6a4-hM3Dq (N= 9) and
Slc6a4-EGFP (N= 9) mice exhibited immobility, mobility, and high mobility during the last 4-min of the forced swim test in vehicle treatment. (i) Latency to
feed by Slc6a4-hM3Dq (N= 17) and Slc6a4-EGFP (N= 17) mice after administration of CNO in an aversive environment following food deprivation
(*po0.05). (j) Latency to feed by Slc6a4-hM3Dq (N= 8) and Slc6a4-EGFP (N= 8) mice after administration of vehicle in an aversive environment following
food deprivation.
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1984; Lam, 2012). Thus, to better mimic the long-term effects
of antidepressants, we decided to take advantage of our
chemogenetic system to chronically and non-invasively
modulate neuronal activity over a long period of time
and then investigate the effects of chronically activating
DRN serotonergic neurons on the behaviors of animals. As
previously described (Jain et al, 2013), CNO (5mg/kg/day)
was administered continuously via drinking water for 3 weeks
(Figure 3a). Then the electrophysiological properties of DRN
serotonergic neurons were assessed to determine whether
these neurons can still be activated by CNO after long-term
CNO stimulation. Bath application of CNO significantly
depolarized (t(3)= 3.842, p= 0.0311) hM3Dq-expressing
neurons but had no effect on EGFP-expressing neurons
(t(7)= 0.989, p= 0.356; Figure 3b and c). Chronic CNO
treatment had no effect on RMP (t(10)= 0.426, p= 0.287,
Figure 3d).
After confirming that hM3Dq DREADD can robustly and
continuously activate serotonergic neurons, we examined
whether chronic activation of DRN serotonergic neurons
could induce anxiogenic and antidepressant drug-like
responses. We found that chronic CNO administration had
no effect on a variety of anxiety measurements, including
the light–dark emergence test (Figure 3e) and center time in
the open-field test (Figure 3f). Importantly, chronic CNO
administration had no effect on locomotor activity, center
Figure 4 Chronic activation of the DRN serotonergic neurons induces a shift of circadian patterns of behavior. (a) Schematic diagram of experimental
procedure of home monitoring system. (b) Percentage of time spent by Slc6a4-hM3Dq (N= 8) and Slc6a4-EGFP (N= 8) mice in the vicinity of novel object
during CNO treatment (*po0.05). (c) Representative locomotor paths occurring 10–20 min after novel object placement for Slc6a4-hM3Dq and Slc6a4-
EGFP mice; the vicinity of the novel object indicated by blue hemicircle (7 cm radius). (d) Mean active state probability in 2-h time bins for Slc6a4-hM3Dq mice
(N= 8) before and during CNO treatment. Dark cycle (DC) indicated by black bar (*po0.05). Active states occurring during the first 4 h of the light cycle for
Slc6a4-hM3Dq (N= 8) mice, aligned by onset time prior to (e) and during (f) CNO treatment. Each row indicates an individual’s active state in order (top to
bottom) of increasing duration. Locomotor, feeding, and drinking behavior indicated in green, orange, and blue, respectively. (g) Mean daily, DC and light cycle
(LC) active state probability for Slc6a4-hM3Dq mice (N= 8) before and during CNO treatment (*po0.05).
Figure 5 Metabolic map of whole brain network activity after activation of DRN serotonergtic neurons. (a) DREAMM reveals alterations in anxiety-related
regions after acute activation of DRN serotonergic neurons. DREAMM responses after acute injection of CNO combined with an open-field exposure
(p= 0.05, relative increase (red) and decrease (blue) in FDG uptake; N= 8, comparison of vehicle vs CNO scans: within-subject comparison). (b) DREAMM
reveals decreases in antidepressant-related regions after chronic activation of DRN serotonergic neurons. DREAMM responses after chronic treatment
of CNO combined with an open-field test (p= 0.001, relative decrease (blue) in FDG uptake; N= 8, comparison of vehicle vs chronic CNO scans: within-
subject comparison). Abbreviations: AOM—anterior olfactory nucleus (medial part), SC—primary somatosensory cortex, MC—primary motor cortex,
Pir—piriform cortex, Cg2—cingulate cortex 2, CT—central thalamic nucleus, MT—medial thalamic nucleus, PAG—periaqueductal gray, IC—inferior
colliculus, PV—paraventricular nucleus of the thalamus, Hb—habenula, TH—thalamus, DG—dentate gyrus, AC—auditory cortex, DS—dorsal subiculum,
LDTg—lateral dorsal tegmental nucleus, DTg—dorsal tegmental nucleus, MPB—medial parabrachial nucleus, MVe—medial vestibular nucleus, CBN—
cerebellar nuclei, and CA1 and CA2—areas of hippocampus.
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time, or light–dark emergence responses in Slc6a4-EGPF
control mice (Supplementary Figures S3–S5).
We next examined whether chronic administration of
CNO leads to antidepressant-like behavioral responses. As
shown in the forced swim test (Figure 3g), a significant
decrease in immobility and an increase in mobility were
observed in Slc6a4-hM3Dq mice when compared with the
Slc6a4-EGFP control mice (genotype × condition interaction,
F(2,72)= 8.35, p= 0.0005), demonstrating a robust and
prolonged antidepressant-like effect from chronic CNO
treatment. Importantly, this antidepressant-like effect was
not observed if Slc6a4-hM3Dq mice (another cohort) were in
a group in which vehicle-only drinking water was consumed
(Figure 3h). There was also no significant difference between
chronic CNO and vehicle administration in Slc6a4-EGFP
control mice (Supplementary Figure S6). Further charac-
terization of this antidepressant-like phenotype resulting
from chronic treatment was evaluated using the novelty-
suppressed feeding paradigm (Santarelli et al, 2003; David
et al, 2009). Chronic administration of CNO induced a
significant reduction in the latency to feed in Slc6a4-hM3Dq
mice (t(32)= 3.913, p= 0.0004) (Figure 3i). However,
chronic administration of vehicle failed to induce the
reduction in the latency to feed in these mice (another
cohort) (Figure 3j). There was also no significant difference
between chronic CNO and vehicle administration in Slc6a4-
EGFP control mice (Supplementary Figure S7). Taken
together, these data provide further evidence that
antidepressant-like behaviors can be induced by chronically
activating DRN 5-HT neurons via hM3Dq DREADD.
We next evaluated the effects of chronic CNO adminis-
tration on the exploratory behaviors of Slc6a4-hM3Dq and
Slc6a4-EGFP mice by introducing a novel object into the
home cage (Figure 4a). The time spent by CNO-treated
Slc6a4-hM3Dq and Slc6a4-EGFP mice within a 7 cm radius
of the object (occupancy time) was then analyzed over 1 h.
Time spent in the vicinity of the object was significantly
enhanced in Slc6a4-hM3Dq mice, relative to Slc6a4-EGFP
mice at the 20 min time point (genotype × time (F(3,42)=
6.39, p= 0.0011), Tukey–Kramer post-hoc test revealed a
significant effect (p= 0.032 at the 20-min time point;
Figure 4b), and the patterns of exploratory interactions were
also different between the two groups (Figure 4c). Impor-
tantly, there was no significant difference between the two
groups in locomotor activities (Supplementary Figure S8).
Chronic Activation of DRN Serotonergic Neurons Alters
Circadian Patterns of Activity
As serotonin has long been implicated in the regulation of
sleep and circadian patterns of activity (Monti, 2008), we
hypothesized that such effects would be observed during
chronic activation of DRN serotonergic neurons. We utilized
a quantitative, robust, and automated procedure to assess
whether the activation of DRN serotonergic neurons could
alter the circadian regulation of physical activity. We
monitored two fundamental and mutually exclusive states
of animals in a home cage environment: active states (ASs)
and inactive states (ISs). In ASs, animals engage in bouts of
feeding, drinking, locomotion, and other behaviors. In ISs,
animals engage in prolonged episodes of low physical activity
(including sleep and resting) occurring exclusively in the nest
(Goulding et al, 2008). We then analyzed these active state
behaviors and calculated the active state probability (ASP) in
both the dark cycle (DC) and light cycle (LC), a measure
which is highly sensitive to circadian rhythm.
For this study, we continuously monitored behavior prior
to (days 8–15) and during CNO treatment (days 22–29)
(Figure 4a). We found that chronic CNO treatment shifted
activity patterns in Slc6a4-hM3Dq mice—a significant over-
all reduction of ASP in DC and a significant enhancement of
ASP in LC (CNO× circadian phase interaction, F
(10,147)= 2.65, p= 0.005, Tukey–Kramer post-hoc testing
revealed significant differences (po0.023) in circadian time
at the 15, 1, and 3 h time points (Figure 4d–g)). Importantly,
this circadian shift was not observed in Slc6a4-EGFP control
mice with chronic CNO treatment (Supplementary Figure
S9). Together, these data indicate that chronic activation of
DRN serotonergic neurons alters the circadian regulation of
activity in animals.
DREAMM Reveals Discrete Patterns of Brain Metabolic
Activity Following Activation of DRN 5-HT Neurons
In an effort to map profiles associated with acute and chronic
DRN serotonin neuronal activation in the open field with
regional brain responses, we used DREADD-assisted meta-
bolic mapping (DREAMM), which enables whole-brain
circuit dissection in response to cell-type-specific signaling
manipulations in behaving rodents (Michaelides et al, 2013).
Concurrent with a reduction in time spent in the center of
the open field, DREAMM revealed that acute hM3Dq
activation of DRN 5-HT neurons led to increased metabolic
activity (ie, FDG uptake) in the cingulate cortex (Cg2), the
right inferior colliculus (IC), the right piriform (Pir), and
primary somatosensory (SC), and motor cortices (MC)
(Figure 5a). In contrast, decreases in FDG uptake were
observed in the periaqueductal gray, anterior olfactory, and
medial and central thalamic areas (MT and CT, respectively)
(Figure 5a). CNO was previously shown to be devoid of
non-specific effects on FDG uptake (Michaelides et al, 2013).
The specificity of DREAMM responses to the behaviors
observed in the open field after acute hM3Dq activation were
validated using both within-subject (scanned after vehicle-
administered open-field sessions) and between-subject con-
trols (Slc6a4-EGFP mice), which did not show changes in
time spent in the center of the open field in response to acute
DRN serotonin neuron activation.
In contrast with the data from acute 5-HT DRN neuronal
activation, DREAMM revealed that chronic DRN 5-HT
neuronal activation produced widespread decreases in
metabolic activity in many forebrain areas. Interestingly, a
large reduction in FDG uptake was observed in hippocampal
regions, specifically in CA1, the left dentate gyrus (DG),
and the left dorsal subiculum (DS) (Figure 5b). Decreases in
FDG uptake were also observed throughout most of the
left habenula (Hb) along with areas of the left MT and CT
regions (Figure 5b). In addition, FDG uptake was reduced
in cortical areas, including the left SC, left primary MC,
and left auditory cortex as well as hindbrain regions, such
as the medial parabrachial nucleus, dorsal and lateral dorsal
tegmental, the medial vestibular, and cerebellar nuclei
(Figure 5b). These widespread decreases in DREAMM
responses were not observed in Slc6a4-EGFP control mice,
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which revealed no overlapping metabolic changes with
CNO-exposed Slc6a4-hM3Dq mice.
To further investigate whether the chronic activation
of hM3Dq led to desensitization of hM3Dq during long-term
treatment, we applied DREAMM technology following an
acute administration of CNO in chronically treated Slc6a4-
hM3Dq mice. DREAMM revealed an intense increase in FDG
uptake in the DRN (Supplementary Figure S10)—supporting
our prior observations (Alexander et al, 2009; Krashes et al,
2011) and that of others (Jain et al, 2013; Carter et al, 2014)
that hM3Dq displays robust and continuous activity even
with long-term stimulation by CNO—also confirming our
ex vivo slice results.
DISCUSSION
Here we reported that both acute and chronic activation of
DRN serotonergic neurons produces a widespread alteration
of functional metabolic activity in the mouse brain, which
can be associated with certain behavioral phenotypes. Our
results provide new insights into the serotonergic regulation
of neural pathways relevant to psychoactive drug action and
describe a pattern of behavior and brain metabolic activation
elicited by selective DRN serotonergic activation.
Both acute and long-term modulation of serotonergic
neuronal activity has been implicated in many therapies that
alleviate depression and other disorders (Kroenke et al,
2001). In addition, SSRIs have also been demonstrated
effective in various animal models, which are utilized as
preclinical screens for these drugs (Willner, 1990). Selectively
increasing DRN serotonergic neuronal activity revealed
analogous antidepressant-like effects in several of these
preclinical behavioral tests. In our study, we found that both
acute and chronic stimulation of DRN serotonergic neurons
produced antidepressant-like behaviors. Interestingly,
anxiety-like behaviors were only seen in acute but not with
chronic stimulation of DRN serotonergic neurons, which
suggests that neuroadaptive changes may occur during
chronic stimulation of the serotonergic system (Faure et al,
2006). The neuroadaptive changes in chronic stimulation
were further supported by our PET imaging data that was
associated with the behavioral phenotypes. Collectively, these
data implicate that DRN serotonergic neurons have a critical
role in mediating antidepressant-like activities.
Serotonin and circadian systems are reciprocally con-
nected both anatomically and functionally. The suprachias-
matic nucleus (SCN), the primary circadian pacemaker,
sends indirect projections to and receives serotonergic
innervations from raphe nucleus (Monti, 2008). Serotonergic
key signaling molecules SERT, 5-HT1B, 5-HT7, and 5-HT2C
receptors are also expressed in the SCN nucleus (Ciarleglio
et al, 2011). Increased serotonergic tone is associated with
wakefulness but not sleep. Pharmacological and genetic
dysfunction of the 5-HT gene network has shown significant
influences on circadian behaviors (Ciarleglio et al, 2011).
Our study provides direct evidence that chronic stimulation
of DRN serotonergic neurons induces alterations in the
circadian regulation of behavior, a finding that is notable in
light of known perturbations of circadian patterns of
behavior in depressive disorders.
Mapping functional brain anatomy associated with acute
and chronic hyper-serotonergic states in mice during
behavior revealed alterations in regions that are implicated
in anxiety and depression. Acute activation during the
expression of an anxiogenic phenotype in the open field
highlighted a mix of changes in FDG uptake in anxiety-
related and sensory-processing nuclei. In particular, sig-
nificant increases in functional metabolic uptake of FDG into
the left cingulate and right piriform cortices was observed.
Importantly, increased cerebral blood flow and glucose
uptake in the cingulate cortex region has been strongly
linked to anticipatory anxiety in humans (Chua et al, 1999;
Javanmard et al, 1999; Straube et al, 2009) and anxiogenic
contextual conditioning in rats (Luyten et al, 2012) while
increases in FDG uptake in the Pir appear after acute
immobilization stress in rats (Sung et al, 2009).
In contrast, chronic activation of DRN 5-HT neurons led to
widespread decreases in FDG uptake, specifically in the left
dorsal and ventral hippocampal regions (CA1, DG, and DS),
CA1 region of the right hippocampus, left Hb, MT, and CT
regions as well as areas of the brain stem and cerebellum.
Importantly, decreases in FDG metabolism in hippocampal
regions have been observed in patients who respond to SSRI
treatment (Mayberg et al, 2000; Kennedy et al, 2001;
Seminowicz et al, 2004). In addition to the hippocampus,
decreased metabolism in the Hb has been linked to
antidepressant drug actions (Shumake et al, 2010). Indeed,
the Hb has been successfully targeted by deep brain stimu-
lation (DBS) to suppress activity in a patient who failed to
respond to antidepressant therapies (Sartorius et al, 2010), and
there is currently an ongoing clinical trial using lateral Hb DBS
for treatment-resistant depression (NCT01798407). Our find-
ings demonstrate the pervasive consequences of selectively
activating a relatively small group of serotonergic neurons in
the dorsal raphe, further elucidating how 5-HT can induce both
anxiety-like activity as well as antidepressant-like responses by
differentially modulating the same neurons.
In conclusion, activation of DRN serotonergic neurons is
sufficient to reproduce the effects of antidepressants that
target 5-HT systems globally. Additionally, we metabolically
mapped the effects of selective DRN serotonergic activation
potentially delineating regional circuitry implicated in
depression. Beyond the insights into the serotonergic
regulation of behavior provided by this work, our findings
highlight the power of DREADD-based chemogenetic
strategies for dissecting the functional consequences of
activation of complex neural pathways.
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